SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is rallying dramatically, fueled by an AI licensing deal in Africa and a palpable short squeeze dynamic amplified by its low float. Community sentiment is overwhelmingly bullish, with traders celebrating significant gains and anticipating further upward movement as short positions face intense pressure within the red-hot AI sector.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending with surging volume, driven by community enthusiasm around its Breakthrough Therapy Designation (BTD) and Fast Track status for Pemvidutide, a MASH/obesity drug candidate. Many investors consider the stock significantly undervalued given its differentiated profile and de-risked pipeline, leading to widespread speculation about potential partnerships or a major acquisition. This strong bullish sentiment, coupled with an active debate around market manipulation and valuation, keeps the stock at the forefront of discussion.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending following its acquisition of a critical minerals flotation facility, bolstering its role as the sole U.S. producer of antimony. The community is actively discussing strong institutional confidence, including significant recent share purchases, and the company's strategic importance in securing domestic supply chains for defense applications. This renewed focus on critical minerals positions the company for continued growth amidst a robust sector trend.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the community eagerly awaits the highly anticipated release of 3-year data from its pivotal EMBARK study for the Duchenne muscular dystrophy gene therapy, ELEVIDYS. Many are buzzing about the potential for significant stock action and a short squeeze, while others ponder the strategic implications of the company's pre-announcement, especially given ongoing discussions about its valuation and the critical need for effective DMD treatments.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies Inc. is trending after appointing an OpenAI expert to its board, a move widely viewed as a significant validation of its quantum-class photonic computing strategy. The community is actively discussing the potential for a substantial rally, drawing comparisons to other exploding AI-related tickers, despite ongoing debate about the company's fundamental prospects. This development is driving strong speculative interest and talks of a potential short squeeze.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is a major talking point amid concerns over the NCAA's call for federal restrictions on college sports betting and the rising influence of prediction markets. Community sentiment is divided, with some investors highlighting recent strong state-level revenue figures and upcoming football season catalysts, while others express frustration over competitive pressures and price weakness.

Equipmentshare.Com Inc - Ordinary Shares - Class A

EquipmentShare.com Inc 

EquipmentShare (EQPT) is trending following its successful IPO and strong debut, with investors and the community actively discussing its T3 technology and national scale as potential drivers for future growth. Many see it as a disruptive force in the equipment rental market, drawing comparisons to established industry leaders.

ShapeShift is a decentralized, multichain cryptocurrency platform that empowers users to swap, track, buy, and earn with over 30,000 assets across the top blockchains such as Bitcoin, Ethereum, Dogecoin, Cosmos, and more. The platform emphasizes financial sovereignty and self-custody, providing an open-source environment where users can engage with the most popular crypto tools and services to trade, earn, and hodl their digital assets. FOX token holders can submit and vote on proposals, helping to shape the future of ShapeShift.

ShapeShift FOX Token

ShapeShift FOX Token ($FOX) is a focal point of intense community debate, with many asserting its severe undervaluation compared to peers like Uniswap, believing its strong DeFi fundamentals position it for a massive breakout as 'altcoin season' approaches. Conversely, a frustrated segment dismisses it as a 'scam' or 'pump and dump' due to its consistent failure to hold gains and underperform the broader market. The polarized discussion hinges on technical setups and a collective yearning for a decisive price movement amidst shifting crypto market dynamics.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. is trending following news that its merger partner, Corvex, has secured a long-term NVIDIA H200 GPU leasing agreement, fueling significant conversation around the company's AI-related prospects. The community is actively discussing a potential short squeeze driven by the stock's reportedly low float, drawing comparisons to recent volatile runners, though some caution that the news may be overhyped and anticipate potential dilution.

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Nuvalent Inc - Ordinary Shares - Class A

Nuvalent is trending following robust clinical trial data for its ALK-positive non-small cell lung cancer (NSCLC) candidate, neladalkib, and positive updates, including Breakthrough Therapy Designations, for its ROS1-selective inhibitor, zidesamtinib. The community is highly engaged, discussing the potential "best-in-class" profiles of its precision oncology pipeline, which has led to significant analyst upgrades and stock rallies. However, some investors are debating its current high valuation relative to earlier development stages and recent insider selling, especially when compared to competitors in the space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


experthiking

experthiking